Literature DB >> 8094897

Dopaminergic treatment of restless legs and rebound phenomenon.

C Guilleminault1, M Cetel, P Philip.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094897     DOI: 10.1212/wnl.43.2.445

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  15 in total

Review 1.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

2.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

3.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation.

Authors:  Roger Kurlan; Irene Hegeman Richard; Cheryl Deeley
Journal:  J Gen Intern Med       Date:  2006-12       Impact factor: 5.128

5.  Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study.

Authors:  Richard K Bogan; Michel A Cramer Bornemann; Clete A Kushida; Pierre V Trân; Ronald W Barrett
Journal:  Mayo Clin Proc       Date:  2010-06       Impact factor: 7.616

Review 6.  Restless legs and periodic leg movements in sleep syndromes.

Authors:  T C Wetter; T Pollmächer
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

7.  [Diagnosis and therapy of restless legs syndrome in the doctor's office].

Authors:  Michael Saletu; Martina Esberger-Chowdhury; Josef Zeitlhofer; Lüder Deecke
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

8.  Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Authors:  J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 9.  Restless legs syndrome: an update on treatment options.

Authors:  Anthony H V Schapira
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Management of restless legs syndrome augmentation.

Authors:  Anne-Marie Williams; Diego Garcia-Borreguero
Journal:  Curr Treat Options Neurol       Date:  2009-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.